Schering Corporation

Merck Sharp + Dohme Corp.

Other

Kristin E Rosner

Joseph A Kozlowski

Wensheng Yu

Janeta Popovici-Muller

Dansu Li

Brian J Lavey

Guowei Zhou

M Arshad Siddiqui

Ling Tong

Vinay M Girijavallabhan

Michael K C Wong

De-Yi Yang

Chaoyang Dai

Bandarpalle B Shankar

Neng-Yang Shih

Seong Heon Kim

Razia Rizvi

Lei Chen

Robert Feltz

Zhuyan Guo

Peter Orth

Vincent Stewart Madison

Judson E Richard

Luke Fire

Aneta Maria Kosinski

Aneta M Micula

Gerald Wayne Shipps, Jr

Umar Faruk Mansoor

Patrick J Curran

Liping Yang

Tong Wang

Seong-Heon Kim

Viyyoor Moopil Girijavallabhan

Zhaoning Zhu

Brian Alexander McKittrick

Timothy J Guzi

Alan B Cooper

Pauline C Ting

Sunil Paliwal

Robert D Mazzola, Jr

Tin-Yau Chan

Yongqi Deng

Lianyun Zhao

David Benjamin Belanger

Henry A Vaccaro

Shing-Chun C Wong

Janet Popovici-Muller

Shankar B Bandarpalle

Aneta Maria Kosinzki

Michael KC Wong

Aneta S Micula

Robert Schering-Plough Corporation Feltz

The compounds are of the class of pyrimidine analogs useful for treating cancer, for example: 

Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof. 

Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF&#x2014;or combinations thereof. 

This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-&#x3b1; combinations thereof. 

Compounds for the treatment of inflammatory diseases

This invention relates to compounds of the Formula (I): 

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-&#x3b1; or combinations thereof.

The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Pyrazolo[1,5a]pyrimidine compounds as antiviral agents

The present invention provides compounds of formula I wherein X and R&#x2013;Rare as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided 

Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents

Growing community of inventors

Watertown, MA, United States of America

Kristin E Rosner